What is ALS Phase 2 Study Creatine/Tamoxifen Clinical Trial?

Category: Others

false

NCT01257581 is a randomized, double blind, selection design, dose finding study of two investigational medications (tamoxifen and creatine) in Amyotrophic Lateral Sclerosis (ALS). Other study names are SDALS-001.

No patients have reported taking ALS Phase 2 Study Creatine/Tamoxifen Clinical Trial.
Last updated:
There are no evaluations for ALS Phase 2 Study Creatine/Tamoxifen Clinical Trial.